Lifecore Biomedical
LFCR
79 hedge funds and large institutions have $114M invested in Lifecore Biomedical in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 15 closing their positions.
58% more call options, than puts
Call options by funds: $778K | Put options by funds: $492K
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
1% more funds holding
Funds holding: 78 → 79 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
2% less ownership
Funds ownership: 72.57% → 70.57% (-2%)
16% less capital invested
Capital invested by funds: $136M → $114M (-$21.8M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
+$2.67M |
| 2 |
Jane Street
New York
|
+$1.14M |
| 3 |
2C
272 Capital
Dallas,
Texas
|
+$1.04M |
| 4 |
3C
325 Capital
New York
|
+$956K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$678K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.62M |
| 2 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
-$1.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.19M |
| 4 |
BlackRock
New York
|
-$862K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$535K |
LFCR Hedge Fund Activity: Q1 2024 in Review
79 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2024, worth a combined $114M — down 16% from $136M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LFCR positions and 15 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Cove Street Capital, adding an estimated $2.67M. The largest seller was Morgan Stanley, cutting an estimated $5.62M.
- 79 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2024, up from 78 in Q4 2023.
- Funds reported $114M of Lifecore Biomedical stock for Q1 2024, down 16% quarter-over-quarter.
- 16 funds opened new Lifecore Biomedical positions in Q1 2024 and 15 closed out, a net change of +1 holder.
- The largest Lifecore Biomedical buyer in Q1 2024 was Cove Street Capital, an estimated $2.67M added.
- The largest Lifecore Biomedical seller in Q1 2024 was Morgan Stanley, an estimated $5.62M sold.
Based on aggregated 13F filings for Q1 2024.